Treatment of malignant phaeochromocytoma with a combination of cyclophosphamide, vincristine and dacarbazine: own experience and overview of the contemporary literature-Reference-Cited by-同舟云学术

Treatment of malignant phaeochromocytoma with a combination of cyclophosphamide, vincristine and dacarbazine: own experience and overview of the contemporary literature

Published:2014-10-24 Issue:1 Volume:82 Page:84-90
ISSN:0300-0664
Container-title:Clinical Endocrinology
language:en
Short-container-title:Clin Endocrinol

Author:

Deutschbein Timo¹,Fassnacht Martin¹,Weismann Dirk¹,Reincke Martin²,Mann Klaus³,Petersenn Stephan⁴

Affiliation:

1. Department of Internal Medicine I; Endocrine and Diabetes Unit; University Hospital Würzburg; University of Würzburg; Würzburg Germany

2. Medizinische Klinik und Poliklinik IV; Klinikum der Universität München; Munich Germany

3. Department of Endocrinology and Division of Laboratory Research; University Hospital Essen; University of Duisburg-Essen; Essen Germany

4. ENDOC Center for Endocrine Tumors; Hamburg Germany

Publisher

Wiley

Subject

Endocrinology, Diabetes and Metabolism,Endocrinology

Reference37 articles.

1. The diagnosis and management of malignant phaeochromocytoma and paraganglioma;Chrisoulidou;Endocrine-Related Cancer,2007

2. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005;Pacak;Nature Clinical Practice Endocrinology & Metabolism,2007

3. Current treatment of malignant pheochromocytoma;Scholz;Journal of Clinical Endocrinology and Metabolism,2007

4. Malignant pheochromocytomas and paragangliomas - the importance of a multidisciplinary approach;Andersen;Cancer Treatment Reviews,2011

5. Clinical predictors and algorithm for the genetic diagnosis of pheochromocytoma patients;Erlic;Clinical Cancer Research,2009

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Activity of Selpercatinib in RET-mutant Pheochromocytoma;The Journal of Clinical Endocrinology & Metabolism;2024-04-25

2. Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert Consensus statement;Nature Reviews Endocrinology;2023-12-14

3. Responses to systemic therapy in metastatic pheochromocytoma/paraganglioma: a retrospective multicenter cohort study;European Journal of Endocrinology;2023-11

4. Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants;The Lancet Diabetes & Endocrinology;2023-05

5. Lenvatinib as a Therapeutic Option in Unresectable Metastatic Pheochromocytoma and Paragangliomas;Journal of the Endocrine Society;2022-03-22